CGNI Stock Overview

A clinical stage biotechnology company, develops heart failure medicines. More details

CGNI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap (£17M)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Cardiogeni PLC Competitors

Arecor Therapeutics

AIM:AREC

UK£19.8m

Synairgen

AIM:SNG

UK£24.0m

ProBiotix Health

OFEX:PBX

UK£16.6m

OptiBiotix Health

AIM:OPTI

UK£17.1m

Price History & Performance

Summary of share price highs, lows and changes for Cardiogeni
Historical stock prices
Current Share Price	UK£0.20
52 Week High	UK£0
52 Week Low	UK£0
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-66.67%

Recent updates

Shareholder Returns

	CGNI	GB Biotechs	GB Market
7D	-20.0%	-4.5%	-1.2%
1Y	n/a	-12.9%	10.0%

Return vs Industry: Insufficient data to determine how CGNI performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how CGNI performed against the UK Market.

Price Volatility

Is CGNI's price volatile compared to industry and market?
CGNI volatility
CGNI Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.4%
Market Average Movement	4.6%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: CGNI's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine CGNI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	n/a	Ajan Reginald	Cardiogeni.com

Cardiogeni PLC, a clinical stage biotechnology company, develops heart failure medicines. The company’s lead product is CLXR-001, a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery. It also develops CLXR-002 and CLXR-003 for heart failure with minimally invasive delivery; and CLXR-004 for use in combination with LVAD device to treat sever heart failure orphan disease indication.

Cardiogeni PLC Fundamentals Summary

How do Cardiogeni's earnings and revenue compare to its market cap?
CGNI fundamental statistics
Market cap	UK£16.81m
Earnings (TTM)	UK£0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is CGNI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CGNI income statement (TTM)
Revenue	UK£0
Cost of Revenue	UK£0
Gross Profit	UK£0
Other Expenses	UK£0
Earnings	UK£0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did CGNI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/20 11:06
End of Day Share Price	2025/02/20 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cardiogeni PLC is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Cardiogeni OFEX:CGNI Stock Report